Liraglutide in Spinal Fluid

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02104037

Acronym

LIRA-CSV

Enrollment

Registered

2014-04-04

Start date

2012-01-31

Completion date

Unknown

Last updated

2014-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liraglutide Blood-brain Transfer

Brief summary

The purpose of this study is to investigate transfer of liraglutide from blood to cerebrospinal fluid.

Interventions

PROCEDURELumbar puncture

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Type 2 diabetes treated with liraglutide 1.8 mg for 1 month and 5% weight loss

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
cerebrospinal fluid concentration of liraglutide	time 60 minutes

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026